China approves world's first CAR-T cell therapy for solid tumors: CARsgen's satri-cel for advanced gastric cancer
By
Jonathan D. Grinstein, PhD
Summary
CARsgen Therapeutics has received approval from China's NMPA for satricabtagene autoleucel (satri-cel; CT041), the world's first CAR-T cell therapy approved for a solid tumor. The therapy targets Claudin18.2 (CLDN18.2)-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in patients who have progressed after two prior lines of treatment. This marks a historic breakthrough in cellular immunotherapy, demonstrating that engineered T-cell therapies can effectively treat solid tumors, not just blood cancers.
Source
bskyChina approves world's first CAR-T cell therapy for solid tumors: CARsgen's satri-cel for advanced gastric cancerinsideprecisionmedicine.comKey quotes
· 3 pulledIn a landmark advance for cellular immunotherapy, CARsgen Therapeutics has received regulatory approval in China for satricabtagene autoleucel (satri-cel; CT041), the first CAR-T cell therapy globally approved for the treatment of a solid tumor.
The National Medical Products Administration (NMPA) of China approved satri-cel for Claudin18.2 (CLDN18.2)-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA) patients who have progressed after two prior lines of therapy.
The gastric cancer treatment proves engineered cellular therapies can treat solid tumors.
You might also wanna read
AI-guided discovery identifies GPNMB as promising CAR T cell target for multiple cancers
Researchers developed an AI-driven framework for discovering CAR T cell therapy targets by integrating single-cell RNA sequencing data from
Engineered immunotherapy drug eliminates aggressive metastatic cancers in clinical trial
Researchers at Rockefeller University have developed an engineered CD40 agonist antibody that successfully eliminated aggressive metastatic
rockefeller.edu·9mo agoAsk HN: What is the latest on treatment of Metastatic Breast Cancer?
Gemma-Based AI Model Identifies Potential Cancer Therapy Pathway Through Conditional Immune Amplification
Researchers used a new 27 billion parameter foundation model called C2S-Scale 27B, built on Google's Gemma family of open models, to discove
blog.google·8mo ago
FDA Approves First Dual-AAV Gene Therapy for Genetic Hearing Loss Under Priority Voucher Program
The FDA has approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy for trea
FDA·2mo ago
EvE Bio Releases Comprehensive Dataset Mapping FDA-Approved Drugs to Cellular Receptors
EvE Bio has created a comprehensive dataset mapping interactions between approximately 1,600 FDA-approved drugs and clinically important hum
owlposting.com·8mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.